Showing results (151-160 of 220) with videos related to

Sort By:
Pageof 22
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|February 15, 2020
Attitudes and Behavior of Health Care Workers Before, During, and After Implementation of Real-Time Location System TechnologyJoan M Griffin, Thomas R Hellmich, Kalyan Sunder Pasupathy, et al.
American Journal of Hematology|December 30, 2014
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasmPamela S Becker, Bruno C Medeiros, Anthony S Stein, et al.
Blood|July 7, 2012
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDSH Joachim Deeg, Bart L Scott, Min Fang, et al.
Blood|January 2, 2014
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemiaJohn C Byrd, John M Pagel, Farrukh T Awan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 27, 2014
Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndromeRaya Mawad, Ted A Gooley, Joseph G Rajendran, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 3, 2014
Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantationRyan D Cassaday, Barry E Storer, Mohamed L Sorror, et al.
Blood Advances|May 16, 2019
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinibFarrukh T Awan, Anna Schuh, Jennifer R Brown, et al.
Blood Advances|April 25, 2020
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemiaCatherine C Smith, Mark J Levis, Olga Frankfurt, et al.
British Journal of Haematology|April 23, 2014
Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical designJack M Lionberger, John M Pagel, Vicky K Sandhu, et al.
British Journal of Haematology|January 30, 2013
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphomaLihua E Budde, Michelle M Zhang, Andrei R Shustov, et al.
Pageof 22